Back to Dashboard

M22-132 (名額需問slot)

Lymphoma•M22-132 (名額需問slot)•Last updated: 2/17/2026

Recruiting

Study Design

Study Drug

Epcoritamab + Polatuzumab +RCHP

Mechanism of Action

CD20+CD3 bispecific Ab

Sponsor

Unknown

Design

I b/ II

Control Arm

-

Criteria

Inclusion Criteria

Newly diagnosed

Age: Phase: I b/ II

Exclusion Criteria

Enrollment

Progress2 / 0

Contact Information

Principal Investigator

Unknown

Study Nurse

李佳玲

Contact Tel

4620